Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment

Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment

Latent reservoir persistence remains a major obstacle for curing human immunodeficiency virus type 1 (HIV-1) infection. Thus, strategies for the elimination of latent HIV-1 are urgently needed. As a bromodomain and extra-terminal (BET) inhibitor, BMS-986158 has been used in clinical trials for advan...

Full description

Bibliographic Details
Main Authors: Xu-Sheng Huang, Ren-Rong Tian, Meng-Di Ma, Rong-Hua Luo, Liu-Meng Yang, Guang-Hui Peng, Mi Zhang, Xing-Qi Dong, Yong-Tang Zheng
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Pharmaceuticals
Subjects:
HIV-1
BET
BMS-986158
latency reversing agent
latent reservoir
Online Access:https://www.mdpi.com/1424-8247/15/3/338

Internet

https://www.mdpi.com/1424-8247/15/3/338

Similar Items